In a report released today, Michael Petusky from Barrington maintained a Buy rating on Merit Medical Systems (MMSI), with a price target of $68. The company’s shares opened today at $56.55.
According to TipRanks.com, Petusky is a 4-star analyst with an average return of 4.8% and a 55.8% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Anika Therapeutics Inc, Varian Medical Systems, and DENTSPLY SIRONA Inc.
Currently, the analyst consensus on Merit Medical Systems is a Strong Buy with an average price target of $70.
See today’s analyst top recommended stocks >>
Based on Merit Medical Systems’ latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $6.2 million. In comparison, last year the company had a net profit of $10.94 million.
Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is neutral on the stock. Last month, Justin Lampropoulos, the EVP GLOBAL SALES, MKTG & STGY of MMSI sold 8,000 shares for a total of $486,880.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Merit Medical Systems, Inc. engages in the manufacture and market of proprietary disposable medical devices. It operates through Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups.
